Plain-English translation of NCT04008563 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether combining weight loss surgery with a progestin intrauterine device (a small hormone-releasing device placed in the uterus) works better than using the hormone device alone for treating early endometrial cancer or precancerous changes in the uterus. The study is designed for younger women who are overweight or obese and want to preserve their ability to have children in the future, avoiding removal of the uterus.
Obesity is the main reason endometrial cancer is rising rapidly, especially in young women. While the hormone device alone helps some patients, it only works in about 50–70% of cases and many women get the cancer back within two years. Researchers believe that addressing the root cause—obesity—at the same time might make this treatment much more effective.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to one of two groups: one group receives the hormone device plus the option to have weight loss surgery, and the other group receives the hormone device alone. Both groups will have the device placed in the uterus to treat the cancer or precancerous changes. The study lasts 21 months, during which you'll have follow-up visits to monitor your response to treatment and track your health outcomes.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Canada